23% of $100,000 goal
Join a Team
RET is a mutation of the RET gene that results in cancer cells to multiply and spread. RET alterations occur in 2% of non-small cell lung cancers (NSCLC), with a higher percentage of patients being younger (<60) and never-smokers.
RET alterations occur in papillary thyroid cancers, a majority of advanced sporadic medullary thyroid cancers, as well as many other cancers, including pancreatic, colorectal, bladder and breast.
Brittany is a stage IV RET-positive NSCLC survivor who was diagnosed in 2021 and was 36 years old at diagnosis. Read her story here.
RET patients are counting on the development of new medications to overcome resistance mechanisms and, someday, make RET-positive cancer a chronic disease that can be controlled with life-long daily medication.
We support research that will advance our understanding of RET-driven cancers and increase the number and quality of cancer treatments for all RET patients.